The goal of the Illuminating the Druggable Genome (IDG) Program is to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families. IDG began in 2014 and received funding for a three year pilot phase. The pilot phase of the program developed a website, called Pharos, that integrates information about understudied proteins so that researchers everywhere can easily access it, catalyzing their own research and helping them find new proteins that may be of interest. In addition, IDG supported researchers developed technologies to enable the study of understudied druggable proteins in a high throughput manner. During 2017, IDG was approved for a second stage of funding, called the Implementation Phase. During the Implementation Phase, IDG aims to expand the informatics tools developed in the Pilot Phase, elucidate the function of understudied proteins from three key druggable protein familes (GPCRs, ion channels, and kinases), and disseminate the IDG-generated resources to the greater scientific community.
The IDG program was funded as a three-year pilot starting in 2014 with two goals. The first goal was to integrate information about understudied druggable proteins from disparate sources into a single informatics site. The second goal was to foster technology development to enable the determination of function and therapeutic potential of understudied druggable proteins at sufficient scale. The program is on track to be successful in accomplishing both of these goals.
The Implementation Phase of the IDG Program will capitalize on the information gathered and the technologies developed in the first three years to elucidate the function of the unstudied proteins of the druggable genome.
Specifically, the Implementation Phase of the program is intended to:
- Expand the informatics tools developed in the Pilot Phase to include additional data and allow users to access a wide range of information on sets of proteins. This goal will be supported by the Knowledge Management Center (KMC.) The KMC identifies and scientifically justifies the data and resources it gathers, enabling the biomedical community to easily identify and prioritize protein targets within any gene family for further study. The KMC will be managed by Dr. Tudor Oprea from the University of New Mexico Health Science Center and Drs. Avi Ma'ayan and Joel Dudley from the Icahn School of Medicine at Mount Sinai.
- Elucidate the function of understudied proteins from three key druggable protein families: non-olfactory G-protein coupled receptors (GPCRs), ion channels, and protein kinases. This goal will be supported by three Data and Resource Generation Centers (DRGCs.) The objectives are to establish a set of integrated technology platforms and generate novel data and tools revealing the molecular, cellular, and/or physiological role of understudied proteins in these three families. Dr. Bryan Roth, Dr. Brian Shoichet, and Dr. Gary Johnson at the University of North Carolina at Chapel Hill have been awarded grants to fund DRGCs that study GPCRs and kinases. Dr. Lily Jan and Dr. Michael McManus from the University of California at San Francisco have been awarded a grant that supports a DRGC to study ion channels.
- Disseminate the IDG-related resources and data to the great scientific community. This goal will be supported by the Resource Dissemination and Outreach Center (RDOC.) The overall goals of the RDOC are to ensure facile access to resources, including reagents, for the research community and to facilitate collaboration and communication among IDG Consortium participants. The RDOC will be managed by Dr. Stephan Schürer from the University of Miami School of Medicine and Drs. Larry Sklar and Tudor Oprea from the University of New Mexico Health Science Center.
This page last reviewed on June 1, 2018